Regeneron to present new Libtayo and cancer-associated thrombosis data at ESMO 2026

Regeneron will present new clinical data across several tumour types and cancer-associated complications at the 2026 European Society for Medical Oncology Congress in Madrid.

The company plans to share 10 abstracts covering cutaneous squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, melanoma and cancer-associated thrombosis.

A major focus will be longer-term findings from the Phase III C-POST study evaluating Libtayo, also known as cemiplimab, as adjuvant treatment for adults with high-risk cutaneous squamous cell carcinoma following surgery and radiation.

The late-breaking presentation will include overall survival findings after approximately three and a half years of follow-up.

Regeneron said the results will add to evidence supporting adjuvant Libtayo in patients with a high risk of disease recurrence.

The company will also present the final analysis from a Phase II study of Libtayo given before surgery in patients with stage II to IV cutaneous squamous cell carcinoma.

This dataset represents the most mature results available from patients receiving neoadjuvant cemiplimab before surgical treatment.

Additional skin cancer data will include longer-term survival follow-up from a Phase I study evaluating fianlimab in combination with cemiplimab in advanced melanoma.

Regeneron will also report new findings in non-small cell lung cancer.

One analysis from EMPOWER-Lung 3 Part 2 will assess the relationship between objective tumour response and patient-reported outcomes among patients receiving cemiplimab plus chemotherapy.

A separate observational study, CEMI-LUNG, will provide real-world evidence on the effectiveness and safety of cemiplimab in patients with advanced NSCLC across Europe.

The company’s ESMO programme also includes further research in ovarian cancer.

One analysis will examine associations between circulating tumour DNA, CA125 and HE4 biomarkers and survival outcomes among patients with platinum-resistant ovarian cancer treated with ubamatamab.

An additional trial-in-progress presentation will provide an update on ubamatamab in combination with other targeted therapies for recurrent ovarian or endometrial cancer.

Regeneron is also expanding its oncology research into cancer-associated thrombosis.

New data will evaluate Factor XI targeting antibodies cenvacibart and amrecibart as potential approaches to reducing venous thromboembolism in people with cancer.

The programme includes an update on the Phase III ROXI-CAT-II study of cenvacibart for the treatment and secondary prevention of venous thromboembolism in patients with solid and haematological cancers.

A Phase II subanalysis will assess amrecibart and cenvacibart for prevention of catheter-associated venous thromboembolism in patients with active cancer undergoing peripherally inserted central catheter placement.

Regeneron will also present pharmacokinetic and pharmacodynamic modelling from the ROXI-CATH programme examining the extent of Factor XI pathway inhibition with cenvacibart.

Israel Lowy, MD, PhD, Clinical Development Unit Head of Oncology at Regeneron, said the company’s ESMO programme reflects a broader strategy that includes both direct cancer treatment and complications arising from the disease.

Several uses highlighted in the presentations remain investigational, including neoadjuvant Libtayo in cutaneous squamous cell carcinoma, ubamatamab, cenvacibart and amrecibart.

---

---

Related Topics and Keywords

amrecibart, Biopharma, C-POST, cancer-associated thrombosis, cemiplimab, cenvacibart, clinical trials, CSCC, CUTANEOUS SQUAMOUS CELL CARCINOMA, ESMO 2026, Factor XI, fianlimab, Libtayo®, melanoma, non-small cell lung cancer, NSCLC, Oncology, Ovarian Cancer, pharma news, Phase II, phase III, Regeneron, Ubamatamab, venous thromboembolism, VTE